LauraEliseHorvathMD

Oncology • Warrenville, IL

Hematologic Oncology

Physician

Join to view full profile

Dr. Horvath is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Horvath's full profile

Already have an account?

Office
4405 Weaver Pkwy
Warrenville, IL 60555
Phone+1 630-352-5300

Fax+1 630-352-5499

Summary

Dr. Laura Horvath is a hematologist oncologist in El Cajon, CA. She received her medical degree from University of Toledo College of Medicine and has been in practice 19 years. She specializes in hematologic oncology and is experienced in hematologic oncology, and clinical research.

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1998 - 2001
The University of Toledo College of MedicineClass of 1998

Certifications & Licensure

IL State Medical License 2001 - 2026

Clinical Trials

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer Start of enrollment: 2009 Feb 01
Withdrawn
Phase 1
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2011 Aug 15
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

22 citations
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Bhavik J. Pandya, Chi-Chang Chen, Bruno C. Medeiros, Catherine B McGuiness, Samuel Wilson
Journal of Managed Care & Specialty Pharmacy. 2020-04-13
458 citations
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P. D'Angelo, Michelle R. Mahoney, Brian A. Van Tine, James N. Atkins, Mohammed M. Milhem
The Lancet. Oncology. 2018-03-01
40 citations
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
M. A. Fuchs, Chen Yuan, Kaori Sato, Donna Niedzwiecki, Xing Ye
Annals of Oncology. 2017-06-01